Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma

Diffuse large B cell lymphoma (DLBCL) is curable with chemoimmunotherapy in ~65% of patients. One the hallmarks pathogenesis and resistance to therapy DLBCL inhibition apoptosis, which allows malignant cells survive acquire further alterations. Inhibition apoptosis can be result genetic events inhibiting intrinsic or extrinsic apoptotic pathways, as well their modulators, such inhibitor proteins, P53, components NF-kB pathway. Mechanisms dysregulation include upregulation anti-apoptotic proteins downregulation pro-apoptotic via point mutations, amplifications, deletions, translocations, influences other proteins. Understanding factors contributing crucial order able develop targeted therapies that could improve outcomes by restoring cells. This review describes DLBCL, provides a perspective interactions lymphomagenesis, discusses implication for future therapy.